GAITHERSBURG, Md., Oct 08, 2002 /PRNewsire-FirstCall via Comtex/ -- MedImmune,
Inc.'s (Nasdaq: MEDI) third quarter 2002 financial results will be released on
Thursday, October 24, 2002 before the opening of the U.S. financial markets. The
company will also host a conference call and live audio webcast at 8:00 a.m.
Eastern Time following the announcement. During the conference call, MedImmune's
management will discuss the financial results and other business for the
quarter.
The press release and the live webcast can be accessed by going to the Investor
Relations section of the MedImmune website http://www.medimmune.com . Following
the webcast, an archived version of the call will be available at the same
address until October 31, 2002.
MedImmune is a leading biotechnology company focused on researching, developing
and commercializing products to prevent or treat infectious disease, autoimmune
disease and cancer. MedImmune currently markets three products, Synagis(R)
(palivizumab), Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune
globulin intravenous (human)), and has 11 products in clinical testing.
MedImmune employs approximately 1,600 people, is headquartered in Gaithersburg,
Maryland, and has additional operations in Frederick, Maryland, as well as
Pennsylvania, California, the United Kingdom and the Netherlands. For more
information on MedImmune, visit the company's website at
http://www.medimmune.com .
This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions. Actual
results could differ materially from those currently anticipated as a result of
a number of factors, including risks and uncertainties discussed in the
company's filings with the U.S. Securities and Exchange Commission. MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future. The company is also developing several products for potential future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required regulatory clearance or that, even if
such regulatory clearance were received, such products would ultimately achieve
commercial success.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X21225985
SOURCE MedImmune, Inc.
CONTACT: Lori Weiman, Senior Director, Corporate Communications,
+1-301-527-4321, or William Roberts, Manager, Investor Relations,
+1-301-527-4358, both of MedImmune, Inc.
URL: http://www.prnewswire.com
http://www.medimmune.com
Copyright (C) 2002 PR Newswire. All rights reserved.